… Nirmatrelvir and ritonavir was approved based on interim efficacy and safety data from the …
nirmatrelvir and ritonavir or placebo within 5 days of symptom onset. Nirmatrelvir and ritonavir …

… The retrospective cohort was conducted to assess the effect of nirmatrelvir-ritonavir (NMV-r)
on the long-term risk of neuropsychiatric sequela following COVID-19. TriNetX research …

… of Molnupiravir and Nirmatrelvir-ritonavir use in reducing mortality in this population. …
Among these patients, 55.4% were male, almost 40% were from care homes, and 5.1% of these …

… ritonavir slows the breakdown of nirmatrelvir to increase its therapeutic benefit. Nirmatrelvir
plus ritonavir … increased nirmatrelvir exposure; therefore, nirmatrelvir plus ritonavir can be …

… patients for each of the nirmatrelvir/ritonavir and supportive care groups. In the
nirmatrelvir/ritonavir group, 300 mg nirmatrelvir with 100 mg ritonavir was administered orally every …

… We found that almost half of patients treated with nirmatrelvir/ritonavir developed an AE,
mainly represented by dysgeusia. Although AEs were usually mild, dysgeusia and …

… should be given in health-care facilities with trained staff to manage … , molnupiravir and
nirmatrelvir–ritonavir will primarily be … care centres, hospital pharmacies (or similar health-care …

… of nirmatrelvir/ritonavir therapy with time to hospitalization by estimating adjusted HRs and
assessed the impact of nirmatrelvir/ritonavir on … regarding long-term care facility residence, we …

… Indeed, recent reports have shown that nirmatrelvir/ritonavir use in the nursing home
setting (where frail patients are often concentrated) has been suboptimal [33]. Interventions to …

… of nirmatrelvir–ritonavir supports the … nirmatrelvir–ritonavir was dispensed had
symptoms for more than 5 days or were asymptomatic—populations in which nirmatrelvir–ritonavir …